ASH 2018 | CASSINI: can we prevent thrombosis in cancer patients who are at risk?
It’s a well-known fact that cancer patients are at risk of developing blood clots, which can affect their quality of life and even have devastating consequences to their life. The CASSINI study looks at the use of rivaroxaban to prevent the development of blood clots in patients with solid tumors and lymphomas. In this video, Alok Khorana, MD, of the Cleveland Clinic, Cleveland, OH, discusses the details and results of the study presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up